Bonesupport Holding Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Torbjorn Skold
İcra Kurulu Başkanı
SEK 4.1m
Toplam tazminat
| CEO maaş yüzdesi | 27.77% |
| CEO görev süresi | 1yr |
| CEO sahipliği | 0.03% |
| Yönetim ortalama görev süresi | 6.3yrs |
| Yönetim Kurulu ortalama görev süresi | 4.3yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jul 20
BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions
Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.Analiz Makalesi • Jul 19
Results: Bonesupport Holding AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
It's been a mediocre week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, with the stock dropping 16% to...
Anlatı Güncellemesi • Jun 17
BONEX: Share Buybacks And Margin Strength Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding steady at SEK 373.83, with only very small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E, which point to broadly unchanged expectations for the stock. What’s in the News for Bonesupport Holding Bonesupport Holding has commenced a share repurchase program starting June 9, 2026, following authorization from the Annual General Meeting held on May 12, 2026.Anlatı Güncellemesi • Jun 01
BONEX: Insider Buying And Profitability Trends Will Drive Future Upside
Analysts have slightly trimmed their price target for Bonesupport Holding to SEK 373.83 from SEK 377.17. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E.Anlatı Güncellemesi • May 13
BONEX: Infection Study Outcomes And Segment Focus Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding broadly steady, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this latest narrative update. What's in the News Bonesupport Holding plans an analyst and investor day focused on how its segment based approach is intended to increase penetration and market share for CERAMENT in prioritized indication areas.Analiz Makalesi • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Anlatı Güncellemesi • Apr 23
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.Anlatı Güncellemesi • Apr 07
BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).Anlatı Güncellemesi • Mar 24
BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.Yeni Anlatı • Mar 12
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 10
BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
Yeni Anlatı • Feb 25
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 23
BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Analiz Makalesi • Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Key Insights Bonesupport Holding's estimated fair value is kr293 based on 2 Stage Free Cash Flow to Equity Current...Anlatı Güncellemesi • Feb 08
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.Anlatı Güncellemesi • Jan 22
BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).Anlatı Güncellemesi • Jan 07
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.Anlatı Güncellemesi • Dec 24
BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.Anlatı Güncellemesi • Dec 10
BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).Anlatı Güncellemesi • Nov 25
BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Analiz Makalesi • Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Bonesupport Holding AB (publ) ( STO:BONEX ) shares are down a considerable 25...Anlatı Güncellemesi • Nov 07
BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Analiz Makalesi • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Anlatı Güncellemesi • Oct 24
Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Analiz Makalesi • Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Bonesupport Holding AB (publ)'s ( STO:BONEX ) price-to-sales (or "P/S") ratio of 18.3x might make it look like a sell...Analiz Makalesi • Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Bonesupport Holding AB (publ)'s ( STO:BONEX ) recent soft profit numbers didn't appear to worry shareholders, as the...Analiz Makalesi • Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Bonesupport Holding is kr508 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
It's been a good week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, because the company has just...
Yeni Anlatı • Mar 19
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.Analiz Makalesi • Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Shareholders of Bonesupport Holding AB (publ) ( STO:BONEX ) will be pleased this week, given that the stock price is up...Analiz Makalesi • Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
The market wasn't impressed with the soft earnings from Bonesupport Holding AB (publ) ( STO:BONEX ) recently. Our...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | SEK 214m |
| Mar 31 2026 | n/a | n/a | SEK 185m |
| Dec 31 2025 | SEK 4m | SEK 1m | SEK 142m |
Tazminat ve Piyasa: Torbjorn 'nin toplam tazminatı ($USD 422.01K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.18M ).
Tazminat ve Kazançlar: Torbjorn şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Torbjorn Skold (49 yo)
1yr
Görev süresi
SEK 4,123,000
Tazminat
Mr. Torbjörn Sköld is Chief Executive Officer of Bonesupport Holding AB (publ) from September 1, 2025. He serves as Member of the Supervisory Board at aap Implantate AG since August 15, 2025. He served as...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chief Executive Officer | 1yr | SEK 4.12m | 0.026% SEK 3.8m | |
| Chief Financial Officer | 7.8yrs | SEK 3.01m | 0.11% SEK 15.6m | |
| Executive Vice President of Global R&D and Operations | 4.8yrs | Veri yok | 0.038% SEK 5.5m | |
| Executive Vice President of Global Marketing | 3.7yrs | Veri yok | 0.019% SEK 2.8m | |
| Executive Vice President of Human Resources | 8.9yrs | Veri yok | 0.024% SEK 3.5m | |
| Executive VP of Medical & Clinical Affairs and Chief Medical Officer | 9.4yrs | Veri yok | 0.17% SEK 24.0m | |
| GM & Executive VP of Commercial Operations of EUROW | 6.8yrs | Veri yok | 0.028% SEK 4.1m | |
| GM & Executive VP of Commercial Operations of US | 6.3yrs | Veri yok | 0.048% SEK 7.0m | |
| Executive Vice President of Quality Management & Regulatory Affairs | 2.2yrs | Veri yok | 0.0038% SEK 554.3k |
6.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: BONEX 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Director | 16.7yrs | SEK 568.00k | 0.42% SEK 61.1m | |
| Independent Chairman of the Board | 9.7yrs | SEK 1.28m | 0.23% SEK 32.7m | |
| Director | 1.3yrs | SEK 329.00k | 0.0085% SEK 1.2m | |
| Independent Director | 4.3yrs | SEK 854.00k | 0.0051% SEK 740.1k | |
| Director | less than a year | SEK 8.32m | Veri yok | |
| Independent Director | 4.3yrs | SEK 585.00k | 0.041% SEK 6.0m |
4.3yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BONEX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/15 18:10 |
| Gün Sonu Hisse Fiyatı | 2026/09/15 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bonesupport Holding AB (publ) 8 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |